Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Abbott Sublicenses Lateral Flow Technology to Calypte

By HospiMedica staff writers
Posted on 23 Aug 2004
A sublicense for certain worldwide rights to patents relating to the design, manufacture, and sale of lateral-flow rapid diagnostic tests has been granted by Abbott Laboratories (Abbott Park, IL, USA) to Calypte Biomedical Corp. More...
(Pleasanton, CA, USA).

Under the terms of the agreement, Calypte was granted certain worldwide rights to use a family of patents known as the Guire/Swanson patents. The technology underlying these patents is fundamental to all lateral-flow rapid diagnostic tests. At the recent International AIDS Conference in Bangkok (Thailand), there was a focus on efforts to quickly identify people with HIV more quickly. Calypte plans to offer a menu of tests providing the HIV testing community with the option to choose from a complete line of rapid tests that can be used to test urine, oral fluid, and blood.

"We are pleased to have received a license to the Guire/Swanson patents from Abbott,” said Dr. Richard George, CEO of Calypte. "The technology covered by these patents is critical to the design of lateral-flow rapid tests. We believe it is one of the essential licenses that will provide us the freedom to manufacture and sell our emerging HIV rapid diagnostic tests in the U.S. and around the world.”




Related Links:
Abbott
Calypte

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Aspiration System
VACUSAFE
New
POC Immunoassay Analyzer
Procise DX
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.